Abstract

Purpose

To evaluate the effect of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection on central choroidal thickness (CCT), central macular thickness (CMT) and best-corrected visual acuity (BCVA) in diabetic macular edema (DME).

Methods

Retrospective, cohort analysis of 90 eyes of 90 patients receiving anti-VEGF therapy for DME. In patients' records, measurements of CCT, CMT, and BCVA before treatment and at 2 years after treatment were recorded. Using enhanced-depth imaging optical coherence tomography (EDI-OCT) images, choroidal thickness and macular thickness measurements were recorded in the subfoveal area and 1 mm nasal to 1 mm temporal to the central foveal area. The baseline and final CMT and CCT values measured from all three quadrants were analyzed statistically.

Results

Mean age of the patients was 59.60 ± 9.78 (range, 40–77) years. Mean baseline nasal-CT 226.4 ± 52.5 µm, central-CT 243.2 ± 51.1 μm and temporal-CT 224.6 ± 47.9 μm. Mean final nasal-CT 220.0 ± 50.2 µm, central-CT 235.3 ± 53.6 μm, temporal-CT 220.5 ± 48.1 μm (p = 0.122, p = 0.056, p = 0.184, respectively). Mean baseline nasal- MT 385.3 ± 67.7, central-MT 345.5 ± 119.7 μm and temporal-MT 365.0 ± 64.9 μm. Mean final nasal-MT 359.6 ± 59.2 µm, central-MT 306.2 ± 98.4 μm and temporal-MT 353.4 ± 63.3 μm (p = 0.001, p = 0.002, p = 0.234, respectively). The BCVA improved from 0.52 ± 0.44 logMAR at baseline to 0.38 ± 0.33 at final (p = 0.002).

Conclusion

After treatment of diabetic macular edema with intravitreal anti-VEGF injection, CMT and BCVA improved significantly, but CCT did not decrease significantly.

中文翻译：

---

抗血管内皮生长因子治疗糖尿病性黄斑水肿后脉络膜厚度的变化，真实数据，2 年结果

摘要

目的

评估玻璃体内抗血管内皮生长因子 (anti-VEGF) 注射对糖尿病性黄斑水肿 (DME) 中中央脉络膜厚度 (CCT)、中央黄斑厚度 (CMT) 和最佳矫正视力 (BCVA) 的影响。

方法

对接受 DME 抗 VEGF 治疗的 90 名患者的 90 只眼进行回顾性队列分析。在患者记录中，记录了治疗前和治疗后 2 年的 CCT、CMT 和 BCVA 测量值。使用增强深度成像光学相干断层扫描 (EDI-OCT) 图像，在中央凹下区域和 1 mm 鼻部至 1 mm 颞侧中央凹区域记录脉络膜厚度和黄斑厚度测量值。统计分析从所有三个象限测量的基线和最终 CMT 和 CCT 值。

结果

患者的平均年龄为 59.60 ± 9.78（范围，40-77）岁。平均基线鼻-CT 226.4 ± 52.5 µm，中央-CT 243.2 ± 51.1 µm 和时间-CT 224.6 ± 47.9 µm。平均最终鼻 CT 220.0 ± 50.2 µm，中央 CT 235.3 ± 53.6 µm，时间-CT 220.5 ± 48.1 µm（分别为p  = 0.122，p  = 0.056，p  = 0.184）。平均基线鼻-MT 385.3 ± 67.7、中央-MT 345.5 ± 119.7 μm 和时间-MT 365.0 ± 64.9 μm。平均最终鼻-MT 359.6 ± 59.2 µm、中央-MT 306.2 ± 98.4 µm 和时间-MT 353.4 ± 63.3 µm（分别为p  = 0.001、p  = 0.002、p  = 0.234）。BCVA 从基线的 0.52 ± 0.44 logMAR 提高到最终的 0.38 ± 0.33 ( p  = 0.002)。

结论

玻璃体内注射抗VEGF治疗糖尿病黄斑水肿后，CMT和BCVA明显改善，但CCT没有明显下降。